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Abstract
Paxilllin is a multifunctional and multidomain focal adhesion adapter protein which serves an important scaffolding
role at focal adhesions by recruiting structural and signaling molecules involved in cell movement and migration,
when phosphorylated on specific Tyr and Ser residues. Upon integrin engagement with extracellular matrix, paxillin is
phosphorylated at Tyr31, Tyr118, Ser188, and Ser190, activating numerous signaling cascades which promote cell
migration, indicating that the regulation of adhesion dynamics is under the control of a complex display of signaling
mechanisms. Among them, paxillin disassembly from focal adhesions induced by extracellular regulated kinase (ERK)-
mediated phosphorylation of serines 106, 231, and 290 as well as the binding of the phosphatase PEST to paxillin have
been shown to play a key role in cell migration. Paxillin also coordinates the spatiotemporal activation of signaling
molecules, including Cdc42, Rac1, and RhoA GTPases, by recruiting GEFs, GAPs, and GITs to focal adhesions. As a major
participant in the regulation of cell movement, paxillin plays distinct roles in specific tissues and developmental stages
and is involved in immune response, epithelial morphogenesis, and embryonic development. Importantly, paxillin is
also an essential player in pathological conditions including oxidative stress, inflammation, endothelial cell barrier
dysfunction, and cancer development and metastasis.
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Background
Paxillin is a main component of focal adhesions (FAs) and
plays an important role in the transduction of extracellular
signals into intracellular responses, triggered by the engage-
ment of integrins with the extracellular matrix (ECM). As a
scaffolding protein, paxillin contributes to the recruitment
of specific kinases and phosphatases, cofactors, oncopro-
teins, and structural proteins, involved in intracellular sig-
naling cascades (Fig. 1). The activation of these pathways
ultimately leads to the reorganization of the actin cytoskel-
eton and the assembly/disassembly of focal adhesions (FAs)
required for cell attachment, spreading, and migration [1].
Paxillin is not only recruited at nascent FAs at the cell front
for the assembly of adhesion complexes but also required
for the disassembly of FAs at the rear end of the cell during
cell movement and migration [2, 3]. Hence, paxillin may
exert positive or negative effects on cell migration [4]. Al-
though paxillin is mainly localized at FAs, it is also present
at cytoplasmic and nuclear locations, where it may affect
gene transcription, thus acting as a direct link from the
plasma membrane and the cytoskeleton to the nucleus [5].
In spite of its inclusion in protein complexes with cytoskel-
etal proteins and enzymes, paxillin does not exhibit enzyme
activity but provides docking sites for other proteins to
facilitate the assembly of multiprotein complexes.
The paxillin family
The paxillin family genes include paxillin (PXN), Hic-5
(TGFB1I1), and leupaxin (LPXN), which share binding se-
quences for several interacting proteins but differ in distri-
bution and specific functions [6]. Paxillin is expressed in
most tissues analyzed, with the lowest level of expression
found in the nervous system. In contrast, Hic-5 expression
is restricted: whereas epithelial cells do not express Hic-5,
this protein is highly expressed in the smooth muscle, par-
ticularly in the vascular muscle. As a functional difference
between these homologous proteins, whereas the lack of
expression of paxillin in embryonic development is lethal,
the deletion of Hic-5 results in minor alterations in the
vascular system development. Although leupaxin expres-
sion was suggested to be restricted to leukocyte cell
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lineage, leupaxin was recently identified in cells from di-
verse lineages. Regarding functional relations among pax-
illin family members, the increase in Hic-5 or ectopic
expression of leupaxin has been shown to prevent paxillin
phosphorylation and its direct interaction with proteins
involved in downstream signaling [6, 7].
The paxillin gene
The PXN gene is highly conserved among species: ortho-
logs of human PXN [8] have been identified in 168 organ-
isms [9]. Human PXN gene is located on chromosome
12q24 and contains, at least, 20 exons within its 55 kbp
length (Fig. 2a). Four isoforms derived from alternative spli-
cing have been described: Isoform 1(α) represents canonical
paxillin [9]. Isoform 2(β) results from the insertion of exon
15, and isoform 3(γ) derives from the use of an alternative
5′-donor site for exon 16. Isoform 4(δ) shares isoform 1
structure, except for a shorter N-terminal domain, derived
from the use of an alternative transcription initiation site in
exon 2 [10] (Fig. 2). Paxillin isoforms exhibit different ex-
pression patterns, α form being the most widely expressed,
whereas the expression of the β isoform is more restricted,
and that of paxillin γ is related to specific cell differentiation
stages [11, 12]. Paxillin δ seems to be exclusively expressed
in epithelial cells [10]. Remarkably, at least 26 additional al-
ternative splice variant messenger RNAs (mRNAs) derived
from automated computational analysis are predicted in
the Genebank (Additional file 1), suggesting that paxillin
might have additional isoforms whose functional role re-
mains to be established.
Bioinformatic analysis of PXN promoter region (Ensembl
Regulatory Element ENSR00000091396) results in a 3401-
bp region, 1271 bp upstream and 2130 bp downstream the
transcription start site (TSS), and contains a number of
putative binding sites for several transcription factors in-
cluding AP-1, CREB, STAT3, c-Jun, and c-Myc [13]. The
regulatory elements which have been experimentally vali-
dated are shown in Fig. 2b [14–16].
MicroRNAs (miRNAs) are small noncoding RNAs that
serve as negative regulators of gene expression [17] and
have been suggested as key players in the regulation of
tumor cell proliferation and invasion [18]. Among these,
miR-212, miR-132, miR-145, miR-137, and miR-218 have
been shown to target the 3′UTR region of PXN. Further-
more, their levels are inversely correlated with PXN ex-
pression in gastric cancer cell lines, colorectal cancer, as
well as in non-small cell lung cancer [19–23]. Therefore,
the expression of these miRNAs has been proposed as
predictive of tumor malignancy and as therapeutic factors.
Structure of paxillin protein
Paxillin is an adapter protein containing five repetitive
leucine-rich LD (Leu-Asp) motifs located at the N-
terminus (LD1 to LD5) and four cystein-histidine-
Fig. 1 Paxillin at focal adhesions. As a major component of FAs, the phosphorylation of paxillin by FAK upon integrin activation allows the recruitment
of several enzymes and structural molecules. Dynamics of paxillin association with these molecules results in changes in cell movement and migration.
The figure depicts a simplified scheme showing the main components of a focal adhesion complex. The number and composition of the FA complex
and the related signaling pathways may vary in different scenarios, according to the subunit composition of integrin receptors and the specific
signaling pathways activated by distinct combinations, in addition to the type and developmental stage of the cell [44]
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enriched LIM domains at the C-terminus. Additionally,
it contains a proline-rich sequence that anchors SH3-
containing proteins, located within the N-terminus, as
well as numerous serine and tyrosine residues through-
out the protein, which bind to SH2 domains (Fig. 3).
The LD motifs form amphipathic helices with leucine
residues laterally aligned on the helix backbone, thus gener-
ating a hydrophobic patch surrounded by negatively
charged aspartic and glutamic acid residues [24]. LD do-
mains provide docking sites for FA-associated proteins in-
cluding tyrosine kinases of the Src family, focal adhesion
kinase (FAK), actopaxin, vinculin, talin, integrin-linked
kinase (ILK), p21-activated kinase (PAK), as well as the
ARF-interacting adapters, G-protein-coupled receptor
kinase-interacting proteins (GIT1/GIT2), ADP-
ribosylation-interacting protein (ARF), and GTPase-
activating proteins (GAPs). FAK interacts with paxillin at
an evolutionary preserved LD consensus motif
(LDLLXXLL), identified as the binding site for FAK and
vinculin [25]. However, in the absence of the four C-
terminal LIM domains, the binding of FAK and vinculin to
the LD domains is insufficient for directing paxillin to the
proper location. In fact, the C-terminal domain of FAK
contains a ~150 amino acid “focal adhesion targeting (FAT)
region” as well as binding sequences for paxillin and talin.
Moreover, although FAK is recruited from the cytoplasm to
adhesion sites by paxillin, FAK interaction with N-terminal
paxillin domains is not required for paxillin localization at
focal adhesions [26]. Particularly, the LD4 domain has been
shown to anchor signaling proteins such as GIT1 and paxil-
lin kinase linker p95 in addition to FAK. The proline-rich
sequence at the N-terminal also provides a binding site for
SH3 domains of the Src family and associates with the tyro-
sine phosphatase PTP-PEST known to regulate cell spread-
ing and migration [5, 27]. Interestingly, the LD motifs also
serve as docking sites for the E6 oncoprotein of bovine pap-
illomavirus type 1, whose binding to paxillin is closely asso-
ciated with disruption of the actin cytoskeleton and cell
transformation by papillomavirus E6 oncoproteins [28].
Noticeably, differences between paxillin isoforms reside at
the N-terminal region: Isoforms 2(β) and 3(γ) contain, re-
spectively, 34 and 48 amino acid inserts downstream the
LD4 motif [11]. Isoform 4(δ) has a shorter N-terminus than
isoform 1(α), lacking the LD1 motif, the proline-rich region,
and the key phosphorylation sites Tyr31 and Tyr118 [10].
The C-terminal region of paxillin is common to all
isoforms and contains four cystein-histidine-enriched
LIM domains, which are involved in protein-protein in-
teractions, and function as an anchor to the plasma
membrane. Specifically, the LIM3 domain is responsible
Fig. 2 Human paxillin gene map. a Exon–intron organization. The gene spans over 55 kb of genomic region in chromosome 12q24 and contains at least
20 exons (shown in boxes). Exons contained in isoforms 1–4 are shown in color, whereas exons contained in predicted alternative splice variants are shown
as white boxes. The alternative initiation sites, as well as the alternative 5’ donor sites or 3’ acceptor sites are depicted with dashed lines. The assembly of
isoforms 1–4 is shown below. The position of the exons, as well as their inclusion in the different isoforms, is shown in Additional file 1. The nucleotide
sequence of the human paxillin genomic sequences (Gene ID: 5829) containing exons and introns corresponds to GenBank with accession number
NC_000012; REGION: complement (120210439..120265771) GPC_000001304. b Promoter region. Ensembl Regulatory Element ENSR00000091396 contains
PXN promoter. This region spans 3401 bp region: 1271 bp upstream and 2130 bp downstream the transcription start site (TSS). Only experimentally
validated regulatory elements are shown [14–16]
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for targeting paxillin to FA sites. Of notice, the serine/
threonine phosphorylation at LIM2/3 domains coopera-
tively potentiates the localization of paxillin to FAs
(Fig. 3) [26]. Paxillin also associates with the adapter
protein 47 (GAG-CRK) [29], a convergence molecule for
signals resulting from cell adhesion as well as from the
activation of growth factor receptors, which interacts
with proteins involved in the regulation of the cytoskel-
eton and tumor metastasis [27, 30].
Paxillin phosphorylation
The function and localization of paxillin is tightly regu-
lated by phosphorylation [27]. In addition to growth fac-
tors and integrin-dependent adhesion to ECM, diverse
stimuli have been shown to induce paxillin phosphoryl-
ation. Although Tyr31 and Tyr118 are the major phos-
phorylation sites, paxillin is phosphorylated at multiple
Tyr and Ser residues (Figs. 3 and 4) [31].
Tyrosine phosphorylation
Integrin binding to ECM promotes paxillin phosphoryl-
ation and recruitment of proteins involved in the assembly
of FAs, including talin, vinculin, tensin, and FAK. Tyr
phosphorylation of paxillin provides a scaffold for the re-
cruitment of tyrosine kinases FAK and Src, which are
activated as a result of adhesion or growth factor stimula-
tion. The subsequent phosphorylation at Tyr88 and
Tyr118 by Src [1, 32], as well as at Tyr118 and Tyr31 at
the N-terminus by FAK, allows paxillin interaction with
downstream effectors, such as p130cas, and the transduc-
tion of external signals into cellular responses mediated by
mitogen-activated protein kinases (MAPKs) (Fig. 4). In
addition to Src, paxillin Tyr118 binding to CRKL SH-2 do-
mains and thereby to a Rac1 signaling complex activated
by DOCK180 has also been described [33]. Although in
vitro studies have shown Tyr118 to be the main residue for
paxillin phosphorylation by FAK, such phosphorylation is
not essential for paxillin localization to focal adhesions. In
fact, the binding site for FAK is located at the N-terminal
domain, whereas the sequence for localization at focal ad-
hesions resides in the C-terminal region of paxillin. The
interaction with FAK however increases the efficiency of
paxillin phosphorylation, in addition to directing the phos-
phorylation of additional tyrosine residues [34]. Since di-
verse stimuli such as lysophosphatidic acid or platelet-
derived growth factor promote Tyr phosphorylation of
paxillin and FAK in distinct cell types during spreading,
the phosphorylation of paxillin by FAK has been suggested
to mediate transduction from cell adhesion to the
reorganization of the cytoskeleton required for cell
Fig. 3 Paxillin structural and functional organization. Human paxillin protein includes 591 amino acids. The N-terminus contains a proline-rich
region that anchors SH3-containing proteins and five leucine-rich LD domains (LD1–LD5), which include docking sequences for the recruitment
of signaling and structural molecules such as FAK, vinculin, and Crk. The C-terminus contains four cystein-histidine-enriched LIM domains, involved
in the anchoring of paxillin to the plasma membrane and its targeting to focal adhesions. Paxillin is phosphorylated in response to cell adhesion
and cytokine or growth factor stimulation: Tyrosine phosphorylation generates interaction sites for signaling molecules, which in turn regulate
paxillin targeting to FAs. Serine phosphorylation, results in a number of functional modifications involved in the regulation of the adhesion
process and cell movement
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movement [35]. Tyrosine phosphorylation of paxillin has
been shown to regulate both the assembly and the turn-
over of adhesion complexes; however, the significance of
this process for adhesion dynamics is still unclear. Whereas
phosphorylated paxillin seems to enhance lamellipodial
protrusions, non-phosphorylated paxillin has been found
essential for fibrillar adhesion formation and fibronectin
fibrillogenesis. Recent data show that FAK preferentially in-
teracts with phospho-tyrosine paxillin, which is implicated
in high turnover of focal complexes and translocation of
FAs [32].
Serine phosphorylation
The N-terminal domain of paxillin contains a number of
serine/threonine phosphorylation sites, which become
phosphorylated during cell migration. Recent studies sug-
gest that paxillin turnover, including its degradation by
the proteasome, is also regulated by serine phosphoryl-
ation during migration. Among the kinases that phosphor-
ylate paxillin at Ser/Thr residues, the phosphorylation of
Ser178 by JUN N-terminal kinase (JNK) is required for
cell migration [36, 37]. On this line, Ser126 phosphoryl-
ation by the sustained activation of Raf/MEK/ERK, and of
Ser130 by glycogen synthase kinase 3 (GSK3), has been
shown to induce the translocation of paxillin from FAs to
the cytosol (Fig. 4) [38]. Furthermore, paxillin phosphoryl-
ation at Ser126 and Ser130 has also been found to regulate
cytoskeletal rearrangement and cell movement in
lipopolysaccharide-stimulated macrophages, through an
extracellular regulated kinase (ERK)/GSK3 dual-kinase
mechanism, which requires ERK-mediated phosphoryl-
ation of Ser130 for the subsequent phosphorylation of
Ser126 by GSK3 [33]. Additionally, p21-activated kinase
(PAK)-induced phosphorylation of paxillin at Ser273 has
been identified as a critical regulator of Rac activation, cell
adhesion, and protrusion, through a novel mechanism
regulated by FAs [39].
The phosphorylation of serine residues at paxillin LIM
domains has been suggested to regulate paxillin localization
at FAs, as well as cell adhesion to fibronectin. Integrin bind-
ing to ECM promotes the phosphorylation of Ser188 and
Ser190, whereas Ser112, 173, 217, and 259 at LD domains
and Ser501 at LIM3 are substrates for protein kinase A
(PKA). Also, Ser residues 85, 90, 94, 106, 108, 126, and
Ser227 at LD3 domain are phosphorylated by GSK3,
whereas Akt posphorylates Ser173. The serine residues 398
and 403 at LIM1, 457 at LIM2, and 481 at LIM3 are phos-
phorylated not only as a consequence of cell adhesion but
also by angiotensin II stimulation. Additionally, protein kin-
ase C (PKC) has been found to phosphorylate serine resi-
dues 91, 98, 108, 382, and Thr 295 and 540. Moreover, ERK
1/2 which localize to FAs and regulate paxillin disassembly
from adhesion complexes, phosphorylate paxillin at Ser106,
231, and 290 [40, 41].
Although the precise involvement of serine phosphoryl-
ation in the regulation of adhesion dynamics and migra-
tion is not fully understood, the phosphorylation of
Ser272 at the LD4 motif seems to regulate the nuclear-
cytoplasmic localization of paxillin by blocking the nuclear
export of paxillin, thus allowing nuclear accumulation. Re-
cent evidence on this matter shows that nuclear paxillin
promotes DNA synthesis and proliferation, and also
suppresses H19 gene expression, which is a parental im-
printing gene hypothesized to be a tumor supressor [5].
Integrins and focal adhesions
A number of cell types require integrin-mediated attach-
ment to extracellular matrix (ECM) for proliferation and
survival. Integrin binding to ECM results in the Tyr phos-
phorylation of paxillin and FAK, the formation of FAs, and
Fig. 4 Activation of signaling pathways linked to paxillin phosphorylation. The localization of paxillin and the subsequent recruitment of signaling
and adapter proteins are highly dependent on phosphorylation. Tyrosine phosphorylation of paxillin promotes the binding of SH2 domain-
containing signaling proteins. In turn, paxillin is also a target for multiple upstream signaling pathways, which upon phosphorylation of specific
serine residues modulate the expression, turnover, and intracellular localization of paxillin
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the assembly of actin fibers required for strenghthening
and stabilizing cell interaction with ECM [3, 42]. There are
24 known integrin α subunits and 9 β subunits: the particu-
lar combination of two subunits (α, β) generates specific in-
tegrin receptors which mediate the binding to the ECM via
their extracellular domains, and interact via their cytoplas-
mic moieties with cytoskeletal adapter proteins such as
paxillin [43], and also promote adhesion-mediated signaling
through the activation of integrin-associated Tyr kinases,
resulting in the phosphorylation of downstream signaling
molecules. In this line, recent studies on the hierarchical as-
sembly of FAs have shown that the structure of integrin
complexes and the related pathways may vary in different
scenarios according to the subunit composition of integrin
receptors and the specific signaling pathways activated by
distinct combinations [44]. Nevertheless, paxillin recruit-
ment to the leading edge of membrane protrusions is an
early event in the formation of focal adhesions [45], al-
though FAK incorporation to these complexes precedes
that of paxillin. In fact, the inhibition of FAK/paxillin inter-
action results in the absence of FAK from focal adhesions, a
decrease in the phosphorylation of several adhesion pro-
teins and the consequent alteration of cell migration and
invasion (Fig. 3) [3, 46].
Interaction of paxillin with focal adhesion
proteins
The phosphorylation of paxillin at distinct tyrosine and
serine residues depends on the cell type and the specific
stimulus. Paxillin is a well-known substrate for the FAK/Src
complex, which phosphorylates Tyr31 and Tyr118 in dy-
namic adhesions, thus promoting paxillin disassembly from
the adhesion complex. On this line, phosphorylation of
Tyr31, Tyr118, Ser188, and Ser190 has been shown to pro-
mote migration, suggesting their involvement in adhesion
turnover [47]. This assumption is supported by data show-
ing that site-directed mutagenesis of Tyr31/Tyr118 or
Ser178 reduces the disassembly of FAs and delays migra-
tory/proliferative phenotype of endothelial cells. In line with
these findings, the requirement of FAK and paxillin phos-
phorylation for insulin growth factor (IGF)-induced cell mi-
gration [48] has led to the suggestion that paxillin (together
with p38 MAPK activation) could also regulate VEGF-
dependent angiogenic response in this cell type [49]. Fur-
thermore, integrin ligand promotion of mouse and human
endothelial cell mobility has been shown to involve an
ABL1-dependent mechanism, which requires paxillin phos-
phorylation, the formation of FAs, and the reorganization
of the cytoskeleton [50].
FAK
Paxillin incorporation to FAs is conformationally regu-
lated and is essential for the recruitment of FAK and other
scaffolding and signaling molecules involved in FA
assembly. The autophosphorylation of FAK at Tyr397
upon integrin activation generates a binding site for the
SH2 domain of Src tyrosine kinases, thereby recruiting
Src to FAs for the formation of an active FAK/Src kinase
complex which phosphorylates distinct focal adhesion
proteins including FAK, paxillin and p130cas, leading to
the activation of signaling to cell migration [30]. In
addition to Src recruitment, FAK has been shown to
transmit integrin-stimulated signals to JNK. Recently, pax-
illin Ser178 has been identified as a major target for JNK,
and proven essential for integrin-induced cell movement
by means of the JNK–paxillin connection. The activation
of JNK by the association of the small GTPase Rac with
ERK1/2 and the downstream phosphorylation of paxillin
at Ser178 have been proven essential for distinct stages of
cell movement and migration [37]. Paxillin phosphoryl-
ation also allows binding to the SH2/SH3 domains of
CRK, involved in cell mobility through the activation of
Rac [29]. On this line, phospho-paxillin binding to the
SH2 domain of p120RasGAP results in the activation of
p190RhoGAP and the consequent decrease in the activity
of RhoA, which could allow cell movement through the
disassembly of the actin cytoskeleton [51].
In addition to integrins, a diversity of stimuli including
bombesin, lysophosphatidic acid, and PDGF promote pax-
illin tyrosine phosphorylation by FAK at FAs [35, 42].
Whereas the phosphorylation of paxillin at Tyr118 regu-
lates the affinity of FAK binding to paxillin, the dephos-
phorylation of phospho-Tyr118 may retard cell migration
even when accompanied by increased expression of
phospho-FAK Tyr397, which further underlines the im-
portance of paxillin Tyr118 phosphorylation in the full ac-
tivation of the FAK/paxillin complex and the induction of
cell migration.
Of notice, paxillin isoforms exhibit important differ-
ences regarding FAK and vinculin binding. Compared to
paxillin α, isoform β exhibits reduced in vitro binding to
vinculin but equivalent binding to FAK. In contrast, Paxil-
lin γ is defective for FAK binding in vitro but retains
vinculin-binding activity. The reason for these differences
is not clear, since the insertions do not appear to disrupt
the LD4 motif, which binds FAK/vinculin. It is possible
that the insertions disrupt interactions with binding part-
ners that stabilize the association of FAK or vinculin with
paxillin. Alternatively, these insertions may alter the con-
formation of the protein masking recognition of both the
LD2 and LD4 motifs by FAK or vinculin [11].
Vinculin
Paxillin interacts with vinculin at FAs through the C-
terminal region of vinculin which functions as a binding
site for the LD1, LD2, and LD4 domains of paxillin. The
high degree of homology of the FAT region of FAK with
the C-terminal tail of vinculin suggests that vinculin
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oligomers could simultaneously bind the LD2 and LD4 mo-
tifs, thus interfering with FAK binding to paxillin [52, 53].
Not only vinculin phosphorylation at Tyr1065 regulates its
conversion to an open ligand conformation thus allowing
binding to talin, F-actin, and other cytoskeletal-related pro-
teins, but it has also been involved in the regulation of
apoptosis mediated by the ERK1/2 pathway [54]. Hence,
although vinculin and paxillin colocalize at focal adhesions,
these two proteins function independently, and vinculin
could subserve a broader role in cell cytoskeletal dynamics
[55, 56].
Tubulin
Polarized cell migration is essential for normal organism
development and is also a critical component of cancer
cell invasion and disease progression. Directional cell
motility requires the coordination of dynamic cell–ECM
interactions as well as repositioning of the Golgi appar-
atus, both of which are controlled by the microtubule
(MT) cytoskeleton. Dynamic microtubules closely inter-
act with FAs in distinct migrating cells. Examination of
microtubule dynamics associated with FAs showed that
paxillin acts as an upstream regulator of site-specific
microtubule transition from growth to shrinkage (“catas-
trophe”) at specific, paxillin-rich adhesion domains.
Tubulin binds to paxillin LIM2 and LIM3 domains,
which requires the integrity of the paxillin zinc finger se-
quences. Furthermore, replacement of full-length paxil-
lin at adhesion sites by microinjected paxillin LIM2-
LIM3 domains suppressed “catastrophe” exclusively at
adhesions, suggesting that paxillin regulates microtubule
dynamics at adhesion complexes [57].
In addition to its role in FAs, paxillin has been linked to
distinct cellular processes in cells lacking these adhesions.
In hematopoietic T cells, paxillin is constitutively associated
with microtubules and microtubule-organizing centers
(MTOC) in a phosphorylation-independent manner.
Moreover, paxillin association with the peripheral supra-
molecular activation center (pSMAC) contributes to the
reorganization, docking, and specific location of MTOCs.
Along this line, the Src family members Lck (lymphocyte-
specific protein tyrosine kinase) and Fyn are key upstream
mediators of PI3K and MAPK signaling pathways. As a
downstream target of these tyrosine kinases, paxillin has
been proposed to contribute to the reorientation and func-
tion of the MTOC [24] by recruiting Pyk2 to the MTOC
[58]. Paxillin has also been shown to interact with the N-
and the C-terminus of γ-tubulin in T lymphocytes, suggest-
ing that paxillin could be responsible for linking micro-
tubule extremes to filamentous actin cortical termini [59].
Recent work has identified a new and conserved role for
paxillin in the regulation of the post-translational modifica-
tion of the MT cytoskeleton, through an inhibitory inter-
action with the α-tubulin deacetylase HDAC6, mediated by
the proline-rich domain of paxillin. Through this inter-
action, paxillin regulates Golgi organelle integrity as well as
polarized cell invasion and migration in normal and trans-
formed cells [60]. Since FAK-mediated activation of RhoA
has been shown to stimulate MT acetylation [61], it is
plausible that RhoA activation may promote the association
of paxillin and HDAC6 and thus result in HDAC6 inhib-
ition and concomitant enhancement of MTacetylation.
Recruitment of signaling molecules
The protein tyrosine kinase Pyk2 and the tyrosine phos-
phatase PTP-PEST are known regulators of scaffolding and
signaling molecules activated in response to integrin bind-
ing. Integrin-induced increase in intracellular calcium pro-
motes Pyk2 autophosphorylation at Tyr402, essential for its
catalytic activation and downstream signaling via paxillin,
p130cas, Src, Cbl, gelsolin, and PTP-PEST [62]. PTP-PEST
is necessary for integrin-mediated adhesion in endothelial
cells, normal embryonic development, and mouse embryo
viability due to its ability to dephosphorylate cytoskeletal
adapter proteins including p130cas, paxillin, and the actin-
associated PCH-family-member proline-serine-threonine
phosphatase-interacting protein (PSTPIP). Moreover, it as-
sociates with the adapters Grb2 and Shc and, through paxil-
lin, with FAK and Pyk2 tyrosine kinases. Suppression of
this phosphatase induces an increase in the phosphoryl-
ation of its direct substrates p130cas, paxillin, and Pyk2 and
causes defects in cell migration and adhesion [63]. Particu-
larly, binding of PTP-PEST to paxillin LIM domain regu-
lates cell spreading, protrusion formation, and migration by
dephosphorylating p130cas and decreasing the activity of
Rac1 [64]. Direct binding of PTP-PEST to paxillin inhibits
the signaling cascades regulated by the LD4 domain [1, 25].
Although paxillin is not a direct target of PTP-PEST, this
phosphatase can mediate the dephosphorylation of Tyr res-
idues 31 and 118 of paxillin and the resulting inhibition of
Rac, through the dephosphorylation of FAK.
Recruitment and regulation of monomeric
GTPases
The role of paxillin in the promotion of cell migration,
fundamental for wound healing, immune response, angio-
genesis, and embryogenesis, is exerted through binding to
regulators and effecters of the Rho GTPases Rho, Rac, and
Cdc42 following integrin–ECM engagement [65].
Within the family of Rho GTPases, Rac and Cdc42 are
respectively involved in the formation of lamellipodia and
filopodia at the leading edge of migrating cells, whereas
RhoA promotes the maturation of adhesions at the lead-
ing edge together with their disassembly at the rear of the
cell [66, 67]. Paxillin recruitment of the PKL-PIX-PAK
complex to FAs may promote the transition from Rho- to
Rac-mediated assembly of focal contacts in order to facili-
tate membrane protrusion and cell migration, suggesting
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that paxillin may play an important role in regulating sig-
nals from Rho GTPases to the actin cytoskeleton [68].
The activity of Rho GTPases is stimulated by guanine
nucleotide exchange factors (GEFs) and negatively regu-
lated by GTPase-activating proteins (GAPs) as well as by
guanine nucleotide dissociation inhibitors (GDIs) [69],
known to play a role in cell migration [70, 71]. Paxillin
coordinates the spatiotemporal activation of Cdc42,
Rac1, and RhoA GTPases by recruiting GEFs and GAPs
along with specific effecter proteins to FAs, thus regulat-
ing cell adhesion and spreading during polarized cell mi-
gration [66, 67]. Among these regulators, the interaction
of ARF-GAP family members with paxillin LD4 domain
localizes them to adhesions via Arf-GAP2 [64], which
links paxillin to Rho signaling. This interaction is re-
quired for the precise coordination of localized Rac1 ac-
tivity and likely contributes to regulate lamellipodia
extension and adhesion turnover by PAK [68]. Paxillin
may also regulate Arf GTPase activity through the for-
mation of a complex with the Arf family GEF factor
cytohesin-2, mediated by the LIM2 domain of paxillin,
which has been shown to regulate migration through
Arf6 [72].
Paxillin function in specific cells and tissues
A number of upstream signals have been shown to acti-
vate and regulate paxillin (and FAK) biologic activity,
which depends on the cell type, the extracellular stimuli,
the intracellular signals activated by stimulating agents,
and the metabolic state of the cell (Fig. 4). Among these
pathways, PMA-induced ERK activation stimulates phos-
phorylation of paxillin Ser83 by either ERK or p83, which
regulates morphological changes in murine epithelial cells
as well as neurite extension in PC12 rat pheochromocy-
toma cells [37], timocytes and splenocytes [73]. Particu-
larly, the phosphorylation of paxillin at Ser178 carried by
JNK has been shown to regulate migration of cells from
rat bladder tumors, hamster ovary, and human mammary
cancer, as well as the extension of neurites in mouse
neuroblastoma cells. In contrast, JNK-mediated paxillin
phosphorylation is basally prevented in human epidermal
keratinocytes by the blockage of JNK activity by overex-
pression of a dominant-negative form of JNK1 [74].
Paxillin in the eye
Retina
The cell–cell and cell–extracellular matrix interactions
necessary for cell adhesion, migration, proliferation, and
differentiation, are essential for the establishment of the
stratified cellular organization of the retina during em-
bryonic development [75]. The regulation of this process
requires integrin-regulated signaling through paxillin
direct binding to the tail regions of α4 integrins and in-
direct interaction with the tail of β-integrins [76, 77]. On
this line, the specific developmental regulation of paxil-
lin Tyr phosphorylation, together with the colocalization
of Tyr-phosphorylated paxillin with integrin receptors at
adhesion areas in the developing retina suggests the par-
ticipation of paxillin in the regulation of neuronal migra-
tion and neurite extension during retinal development.
Although little is known regarding the possible func-
tion of paxillin in the differentiated retina, the radiation-
induced activation of paxillin by p38 MAPK in retinal
endothelial cells has been shown to trigger cell prolifera-
tion and neovascularization which can be prevented
through the inhibition of paxillin phosphorylation by the
quinic acid derivative KZ-41. This evidence suggests that
uncoupling of p38MAPK-mediated signal transduction
could be a potential strategy for the design of clinical
treatments for radiation retinopathy leading to retinal
neovascularization [49].
Cornea
The corneal epithelium acts as a protective barrier on
the corneal surface and is exposed to physical, chemical,
and biological injuries. The successful healing of corneal
lesions includes cell migration and proliferation, as well
as matrix deposition and tissue remodeling. Among the
factors known to promote this process, EGF stimulation
of human corneal epithelial cell migration requires the
phosphorylation of paxillin by MAPK-JNK at Ser178,
which allows the binding of FAK and the subsequent
phosphorylation of paxillin at tyrosines 31 and 118 [37].
In fact, ERK1/2 activation in response to a corneal lesion
promotes the formation of FAs and the phosphorylation
of FAK and paxillin at the border of the wound, which is
prevented by MEK1 inhibition. These data clearly in-
volve signaling by ERK/FAK/paxillin in the formation of
focal adhesions and the regulation of cell migration asso-
ciated with corneal wound healing [78]. Recent findings
have also revealed that vimentin filaments linked to
paxillin-containing FAs at the lamellipodial tips of the
cells at the wound edge is essential for wound healing in
mock cataract surgery [79].
The phosphorylation of paxillin at Ser178 by c-Jun N-
terminal kinase (JNK) has been shown to be vital for
epithelial cell adhesion and migration. Studies in human
corneal epithelial cells in vivo and in vitro have demon-
strated that transglutaminase (TG)-2 positively regulates
the phosphorylation of paxillin at Ser178, which does
not require stimulation by specific extracellular ligands.
Although the signaling mechanism driving Ser178 phos-
phorylation is poorly explored, paxillin phosphorylation
at this residue facilitates the binding of FAK, which in
turn promotes Tyr31 and Tyr118 phosphorylation and
the subsequent binding of vinculin to paxillin. This evi-
dence suggests that phosphorylation of paxillin Ser178
may be upstream FAK and vinculin, which may be
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sufficient to interfere with post-translational changes
downstream FAK and vinculin [80].
Immune response and inflammation
The innate immune function of phagocytosis of apoptotic
cells, tissue debris, pathogens, and cancer cells is carried
out by resident microglia in the central nervous system
(CNS). In healthy cells, this process is arrested by the re-
cruitment of immune inhibitory receptor SIRPα to the
surface of phagocytes and the resulting activation of sig-
nals that inhibit phagocytosis. Recent work showed that
the activation of SIRPα prevents paxillin phosphorylation
indirectly, through the inactivation of cofilin, induced by
paxillin dephosphorylation at Tyr118. These observations
support a novel mechanism whereby paxillin and cofilin
are targeted to control phagocytosis by phagocytic recep-
tor signaling to the activation of paxillin and cofilin, and
signaling by immune inhibitory SIRPα which promotes
the inactivation of paxillin and cofilin [81].
Blood leukocytes are involved in essential functions in-
cluding the development of the immune system and the
control of the inflammatory response, which requires mi-
gration of leukocytes and lymphocytes from the vascula-
ture, controlled by integrin receptor signaling. Within this
process, paxillin binding to α4 integrin cytoplasmic do-
main induces ligation of integrin α4β1, thus promoting
the signaling events. Since paxillin can associate with non-
receptor tyrosine kinases such as FAK and Pyk2, signaling
from integrins to these kinases may be implicated in the
regulation of leukocyte migration [82, 83].
In inflammatory responses, endothelial cells undergo
morphological changes to allow for the passage of neutro-
phils from the blood vessels to the site of injury or infec-
tion. Recent findings showed a selective loss of paxillin
and FAK from FAs in proximity to transmigrating neutro-
phils in HUVEC endothelial cells. As paxillin dynamics
are partially regulated by FAK, decreases in FAK protein
or disruption of FAK signaling prevents neutrophil trans-
migration, revealing a novel role for endothelial FA pro-
teins paxillin and FAK in the regulation of inflammation
and immune responses [84].
Epithelial morphogenesis
Paxillin serves as an ERK-regulated scaffold for
coordinating FAK and Rac activation, essential for cyto-
skeleton rearrangement involved in epithelial morpho-
genesis [40, 85]. The regulation of FA formation/
turnover and the interaction of FAs with the actin cyto-
skeleton are central events for the morphogenic actions
of distinct growth factors. Among them, hepatocyte
growth factor (HGF) stimulation promotes Src activation
and the recruitment of inactive ERK to paxillin, which
induces ERK activation. The phosphorylation of paxillin
by activated ERK enhances FAK recruitment to nascent
adhesions. Ser83 has been identified as the ERK phos-
phorylation site in murine paxillin, which is essential for
HGF-stimulated paxillin–FAK association, FAK phos-
phorylation, PI3K activation, and the subsequent activa-
tion of Rac [47]. This process allows the disassembly of
specific adhesions surrounding HGF receptor along
morphogenesis, thus promoting lamellipodia formation,
cell spreading, and migration [41].
Embryonic development
Signaling through integrin receptors is importantly in-
volved in developmental processes mainly related to
mesodermal-derived structures. Although evidence
regarding paxillin role in development is scarce, as a
well-known integrin effector, paxillin acts as transducer
of fibronectin receptor signals during early development
by promoting the recruitment and phosphorylation of
FAK, p130cas, and MAPKs [86]. Thus, paxillin and fi-
bronectin seem to regulate some common embryonic
developmental events, by controlling FA dynamics, cell
migration, and spreading [53, 87]. In support of this as-
sumption, the deletion of the paxillin gene in mouse em-
bryos is lethal. Specifically, phosphorylation of paxillin
by PAK (kinase activated by p21) at Ser273 in the chick
(Ser272 in human) has been shown to promote the ad-
hesion and migration of non-neural cells [88]. Also, in
this line, the activity of dipeptidyl peptidase IV family
protease (DPP9) has been shown to be essential for mice
neonatal survival. DPP9 gene silencing or specific inhib-
ition was shown to reduce cell adhesion and migration
required for early embryonic development by decreasing
the phosphorylation of FAK and paxillin [89]. In fact,
the death of paxillin null mice embryos after gastrulation
derives from defective mesodermal development [77].
Evidence has been provided demonstrating FAK and
paxillin involvement in the regulation of cytoskeletal
changes fundamental to neuronal development, such as
the hormonal modulation of FAK and paxillin in the
feminization of the brain. Whereas FAK and paxillin are
highly expressed in the hypothalamus of female rats at
birth, the male tissue shows low expression, which is sig-
nificantly increased by the inhibition of aromatase, sug-
gesting that the combined action of androgens and
estrogens may be important in paxillin regulation along
development [90].
Paxillin in the nervous system
Integrin-dependent functions, such as adhesion, migra-
tion, and proliferation, are critical in the development
and the maintenance of the central nervous system [91].
Integrin-activated signaling, including paxillin phosphor-
ylation, is required for the outgrowth of neurites and the
formation of the glial scaffold in the brain and also for
remodeling and long-term potentiation within synapses.
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Paxillin involvement in focal adhesion dynamics plays an
important role in neurite extension, and is also required
for neurite outgrowth, although the molecular mechan-
ism by which paxillin may regulate these processes is
poorly understood [92]. Recent studies have shown that
neurite outgrowth induced by laminin requires the phos-
phorylation of FAK and paxillin, mediated by AKT/GSK-
3β signaling. This process seems to be essential for brain
development, since the knock-out of laminin induces the
decrease of FAK and paxillin phosphorylation accom-
panied by severe anatomic and neuronal morphological
defects [93]. In addition to serine phosphorylation, tyro-
sine phosphorylation of paxillin has also been shown to
promote neurite outgrowth induced by NGF and EGF-
dependent pathways. Additionally, Nemo-like kinase has
been suggested to control the dynamics of the cytoskel-
eton downstream of NGF signaling, through directly
phosphorylating microtubule-associated protein-1B
(MAP1B) and paxillin at Ser126 [94]. Furthermore,
p38MAPK-mediated phosphorylation of Ser85 on paxil-
lin is also involved in NGF-induced neurite outgrowth in
PC-12 cells, since mutation of paxillin Ser 85 signifi-
cantly inhibits NGF-induced neurite extension. Hence,
the phosphorylation of paxillin at Tyr and Ser residues is
required for NGF-induced neurite extension, probably
through regulating focal adhesion organization [95].
Radial glial cells are known to support neuronal migra-
tion along the development of the nervous system. Al-
though little is known regarding the role of paxillin in this
process, phosphorylation of paxillin at Ser178 has been
shown to play a key role in cell migration in the central and
peripheral nervous systems. During development of the
peripheral nervous system (PNS), intercellular signaling be-
tween neurons and Schwann cells induces the migration of
Schwann glial cells along axons, wrapping individual axons
to form a myelin sheath. In spite of the considerable clinical
importance of myelination, the molecular mechanisms
underlying this process in the peripheral nervous system as
well as within the central nervous system is largely un-
defined. Recent data on this issue have shown that JNK
binds to the first LD region of paxillin and phosphorylates
Ser178 to regulate Schwann cell migration, illustrating that
paxillin provides one of the convergent points of intracellu-
lar signaling pathways controlling neuronal-mediated
Schwann cell migration [96].
Oligodendrocytes (OLs) are the myelinating glial cells
of the central nervous system (CNS). Oligodendrocyte
precursor cells (OPCs) differentiate into oligodendro-
cytes (OLs) in order to form the myelin sheath, which
wraps axons and allows the rapid propagation of action
potentials in the vertebrate nervous system. Studies from
Miyamoto et al. [97] have recently shown that cyclin-
dependent kinase 5 (Cdk5), a proline-directed serine/
threonine kinase enriched in neuronal tissues, directly
phosphorylates paxillin at Ser244 following the induction
of oligodendrocyte differentiation. Since oligodendrocyte
differentiation and myelin sheath formation are pre-
vented by the suppression of Cdk5, paxillin phosphoryl-
ation by Cdk5 seems to be a key mechanism in OL
differentiation and may ultimately regulate myelination.
Paxillin in pathological conditions
Numerous pathological conditions may induce the phos-
phorylation of the focal adhesion partners paxillin and
FAK, with the consequent activation of intracellular sig-
nals leading to the alteration of cell cytoskeleton, cell
division, and cell motility.
Stress and oxidation
Conditions involving oxidation, mechanical traction, or
hypotonic challenge (HTS) have been shown to induce
FAK and paxillin phosphorylation and the translocation/
activation of RhoA. Athough FAK and paxillin tyrosine
phosphorylation is not required for the activation of
RhoA/RhoK signaling, the simultaneous activation of
RhoA/Rho kinases and FAK/paxillin, driven either by
mechanical stress or by receptor activation-induced ATP
release, has been found to promote actin cytoskeleton
reorganization leading to functional repercussion [98].
Oxidative stress is one of the most common apoptosis-
inducing factors in several organs, from the intestinal and
cardiovascular systems to neuronal cells, including the sen-
sory organs [99]. In pathological events involving ische-
mia–reperfusion, reactive oxygen species (ROS), such as
superoxide anion (O2·2), hydrogen peroxide (H2O2), and
hydroxyl radical (HO·), are released by the ischemic tissue.
ROS, particularly the hydroxyl radical (HO·), are capable of
stimulating the tyrosine phosphorylation of paxillin, FAK,
and p130cas in human endothelial cells which, in turn, trig-
gers the activation of signaling cascades that regulate cell
proliferation and differentiation. Importantly, recent studies
show that PAX-FAK-p130cas phosphorylation induced by
intracellular hydroxyl radical (HO·) stimulates polymorpho-
nuclear lymphocyte (PMN) adhesion to human endothelial
cells and their subsequent migration, suggesting an import-
ant role of FAK/PAX activation by ROS in PMN recruit-
ment during inflammation [100].
Endothelial cell barrier dysfunction
The regulation of paxillin phosphorylation seems to be a
target for the control of endothelial cell (EC) barrier func-
tion and its dysfunction induced by oxidative stress, as well
as lipopolysaccharide- and ventilator-induced lung injury.
The release of oxidized phospholipids (OxPLs) into the cir-
culation as a consequence of tissue injury has not only been
shown to contribute to pulmonary endothelial cell dysfunc-
tion and the alteration of vascular barrier function but can
also play a barrier-protective role in human lung ECs
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through Rac- and Cdc42-dependent promotion of actin
reorganization and paxillin accumulation at focal adhesions.
Moreover, phosphorylation of paxillin at Ser273 by PAK1 is
critically involved in the positive feedback regulation of the
Rac-PAK1 pathway, which may contribute to the sustained
enhancement of the EC barrier induced by OxPLs [101]. In
contrast, paxillin Tyr31 and Tyr118 phosphorylation has
been implicated in EC barrier dysfunction causd by OxPL,
through the destabilization of VE-cadherin at adherens
junctions [1]. Although the opening of endothelial cell junc-
tions causes increased permeability, ECs are capable of
enhancing barrier function in the presence of barrier-
enhancing factors such as sphingosine-1-phosphate (S1P),
hepatocyte growth factor (HGF), and hyperosmolality. This
process is driven by HGF- and S1P-dependent modulation
of Rac–Rho signaling which, in turn, requires c-Src/FAK-
mediated phosphorylation of paxillin at Tyr31 and Tyr118
and also at Tyr181 by c-Abl kinase [102, 103].
Cancer
Paxillin involvement in cell migration was initially sug-
gested by the high levels of expression of the phosphory-
lated protein determined in several cancer tissues and
metastatic cancer cells, in parallel to increased epithelial-
mesenchymal transition [104].
A main characteristic of transformed epithelial cancer
cells is the ability to survive and proliferate in the absence
of contact with immobilized ECM [105]. Paxillin is known
to acquire gain of function mutations that are associated
with alterations in the malignant progression of many tu-
mors including breast, lung, prostate, melanoma, and colo-
rectal cancer [106]. Among these, glioblastoma multiforme
(GBM), the most common and malignant type of glioma,
remains one of the most lethal cancers in the central ner-
vous system (CNS). Recent studies have demonstrated that
the overexpression of paxillin at the RNA and protein level
is associated with GBM tumor malignancy and hence, pre-
dictive of poor survival [107]. These data identify paxillin as
a novel prognostic biomarker with potential anti-invasion
therapeutic implications in GBM. On this line, a total of 21
unique paxillin mutations were identified in lung cancer tis-
sue specimens and cell lines. A127T, the most common of
these mutations, increases tumor growth and invasion in
vivo [108]. Importantly, paxillin δ is able to suppress full-
length (α)-paxillin signaling as well as interactions with
actin-binding and integrin-linked proteins due to the lack
of LD1 domain, thus suggesting a potential role in sup-
pressing the migratory phenotype of cancer cells [10].
Recent data show that maximal tyrosine phosphorylation
of paxillin by Src and FAK is required for the induction of
anchorage-independent signal transduction and prolifera-
tion, characteristic of metastatic cells [105, 109]. Along this
line, studies by Sero et al. [110] in embryonic fibroblasts
(MEF) show that paxillin integrates physical and chemical
motility signals by spatially constraining the location of
motile processes, thereby regulating directional migration.
These findings indicate that complex multimeric and
competing interactions on paxillin are required to augment
anchorage-independent cell proliferation in cancer
development.
A growing number of signaling molecules have been
shown to promote or regulate cell migration of cancer
cells through the phosphorylation of paxillin at Tyr118
and Ser178 by FAK, which alters the organization of FAs,
with the consequent promotion of cell motility [2, 111]. In
fact, the increased phosphorylation of these residues is
considered as indicative of metastasis.
Multiple receptor-activated signaling pathways have
been involved in cell transformation and migration under-
lying metastasis in breast cancers. Particularly, paxillin has
been shown to control the signaling of estrogen (17-β es-
tradiol) to FAK/N-WASP/Arp2/3 complex in breast can-
cer cells [112]. On this line, the vitamin A derivative
retinoic acid (RA), frequently used in cancer therapy, has
been shown to induce Src/FAK/PI3K complex signaling to
cell attachment, migration, and invasion mediated by the
rapid activation of the actin-binding protein moesin.
Within this pathway, cell migration of breast cancer cells
is prevented by RA through the regulation of the expres-
sion of Moesin and the downstream inhibition of Src,
FAK, and paxillin activity, providing novel mechanistic
clues for the development of new drugs for cancer treat-
ment [113]. Also on this matter, paxillin has been shown
to be transcriptionally upregulated and phosphorylated by
human epidermal growth factor receptor-2 (HER2) signal-
ing in vitro. Since HER2 overexpression has been involved
in metastatic cancer progression, particularly in breast
cancer, paxillin has been identified as a marker of aggres-
sive breast cancer and a promoter of neoplastic growth
and invasion, supporting its role as a biomarker or thera-
peutic target [114, 115].
Rho/ROCK signaling plays a crucial role in the regula-
tion of FAs and cell motility [116]. The serine/threonine
protein phosphatase inhibitor calyculin A has been shown
to promote focal adhesion assembly upon the inhibition
of the ROCK downstream target serine/threonine myosin
light chain (MLC) phosphatase, and the resulting tyrosine
phosphorylation of FAK, paxillin, and p130cas, thus sup-
porting calyculins as potential anticancer agents [117].
The FAK/paxillin pathway regulates small Rho GTPases
including RhoA, Rac1, and Cdc42, which are critical de-
terminants of cancer cell migration. Importantly, the spe-
cific interaction of Rho GTPases with tumor supressor
deleted in liver cancer-1 (DLC1) has been shown to de-
crease FAK-dependent localization of paxillin at immature
focal adhesions, thus controlling the lifetime of nascent
focal adhesions [118]. Since this process is FAK-
independent in migrated cells, these data indicate that the
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function of paxillin/FAK/RhoA signaling in the control of
cell movement is developmentally regulated. On this mat-
ter, the serine/threonine kinase maternal embryonic leu-
cine zipper kinase (MELK) has recently been shown to
promote cell migration and invasion via the activation of
RhoA and the downstream phosphorylation of FAK and
paxillin. Hence, MELK has emerged as a potential cancer
biomarker [119]. The human phosphatase and tensin
homolog (PTEN) tumor suppressor is mutated at high fre-
quency in a large number of cancers. Recent work in
colon cancer cells has shown that PTEN function as a
tumor suppressor derives from the downregulation of
paxillin expression by the inhibition of PI3K/AKT/NF-kB
signaling. This allows the activation of NF-kB and the pro-
motion of paxillin expression, thus stimulating cell
invasion, migration, and cancer progression [14]. In agree-
ment with this evidence, proteolysis of paxillin by calpain
between the LD1 and LD2 motifs in HeLa cells generates
a carboxy-terminal 55 KDa fragment, similar to delta pax-
illin, which functions as an antagonist of endogenous pax-
illin and may function to limit cancer cell invasion by
preventing the assembly/disassembly of FAs and cell mi-
gration [120, 121].
Recent studies in human pancreatic ductal adenocar-
cinoma cells (PANC-1) have shown that the elevation of
cAMP concentration by distinct stimuli results in the in-
hibition of migration of several PANC cell types in strict
correlation with the inhibition of FA turnover, a highly
significant loss of paxillin from FAs, and the consequent
cessation of ruffling. These data clearly indicate that the
inhibitory effect of cAMP on migration, ruffling, FA dy-
namics, and paxillin localization is mediated by the
downstream activation of PKA, while the inhibition of
this enzyme potentiates migration [122].
Hepatocyte growth factor (HGF)-induced c-Met sig-
naling plays critical roles in the progression of hepato-
cellular carcinoma (HCC). On this line, PKCε-mediated
c-Met endosomal processing was shown to stimulate c-
Met-JNK-induced paxillin (Ser178) phosphorylation,
which is required for cell migration, invasion, and intra-
hepatic metastasis [123].
Conclusions
Cell migration is a complex process essential for embryonic
development, angiogenesis, and wound healing. It involves
cell polarization and extension of protrusions and adhesion
at the leading edge, coordinated with the disassembly of ad-
hesions at the rear end of the cell. Paxillin has progressively
been shown to be crucial for cell movement by recruiting
cytoskeletal elements and signaling molecules involved in
cell attachment, spreading, and migration. Multiple path-
ways have been identified which regulate paxillin function
through the phosphorylation and dephosphorylation of
tyrosine and serine residues. Upon the activation of integrin
receptors, FAK phosphorylation of Tyr31 and Tyr118, as
well as ERK phosphorylation of serines 106, 231, and 290
have been shown to regulate paxillin disassemby from ad-
hesion complexes and to promote cell movement. On the
other hand, binding of PTP-PEST phosphatase was also
found to regulate cell spreading, protrusion, and migration.
These findings reveal a complex interplay between kinases
and phosphatases in the regulation of paxillin function in
cell migration. Paxillin has also been shown to coordinate
the spatiotemporal activation of Cdc42, Rac1, and RhoA
GTPases by recruiting GEFs and GAPs to focal adhesions,
thus allowing the activation of a number of cell migration-
related signaling pathways. As a major participant in the
regulation of cell movement, paxillin plays distinct roles in
different cells and tissues, linked to immune response, epi-
thelial morphogenesis, and embryonic development, as well
as in pathological conditions such as inflammation, oxida-
tive stress, disruption of endothelial cell barrier, and cancer
cell metastasis. The elucidation of paxillin function regula-
tion is crucial for the development of pharmacologic or
clinical strategies aimed to controlling cancer development
and metastasis.
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human paxillin gene (Gene ID: 5829) is 55333 bp. “Homo sapiens
chromosome 12, GRCh38.p7 Primary Assembly,” NCBI Reference
Sequence: NC_000012.12 was used in the elaboration of this table.
Alternative splice variants are organized in columns. The putative exons
are boxed and shown in the first column. The position of 5’-donor sites,
as well as 3’-acceptor sites, is shown in the second column. (XLSX 54 kb)
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